protein
| S100A1 binding |
|
interacting with VIM and SYNM in astrocytes (Jing 2007) |
|
PAX3 is a novel regulator of GFAP transcription, which could bind the promoter region of GFAP and down regulate the GFAP level during the serum-induced astrocyte differentiation of neural stem cells (NSCs) |
|
role of retinoic acid signaling in GFAP expression |
|
PAX3 is a regulator of GFAP transcription, which could bind the promoter region of GFAP and down regulate the GFAP level during the serum-induced astrocyte differentiation of neural stem cells |
|
SIN3A coupled with MECP2 bound to the GFAP promoter and their occupancies were correlated with repression of GFAP transcription |
|
caspase-mediated GFAP proteolysis may be a common event in the context of both the GFAP mutation and excess |
|
histone acetylation in astrocytes suppresses GFAP and stimulates a reorganization of the intermediate filament network |
Candidate gene
| role of GFAP and UCHL1 as candidate biomarkers for pediatric traumatic brain injury (TBI) |
Marker
| marker for astrogliosis, and is a potential biomarker for multiple sclerosis (MS) progression and may have a role in clinical trials for assessing the impact of therapies on MS progression |
|
increased serum GFAP, S100B, ENO2 are associated with acute CO poisoning, and these biomarkers can be useful in assessing the clinical status of patients with CO poisoning |
|
autoantibodies against GFAP could serve as a predictive marker for the development of overt autoimmune diabetes |
|
is a promising diagnostic biomarker for intracerebral hemorrhage (ICH) diagnosis in the early pre-hospital phase |
Therapy target
| |